{"product_id":"9781461379164","title":"Blood Stem Cell Transplantation","description":"\u003ch1\u003eBlood Stem Cell Transplantation\u003c\/h1\u003e \u003ch2\u003eWinter, Jane N.\u003c\/h2\u003e \u003cp\u003e\u003cem\u003eBlood Stem Cell Transplantation\u003c\/em\u003e conveys the excitement  that accompanies the newest developments in hematopoietic stem cell  transplantation. Some of the applications that stand to impact this  field most significantly are based on recent advances in the  biological sciences, as demonstrated by the chapters on gene therapy,  on the detection of minimal residual disease using molecular  techniques, and on the use of radioimmunoconjugates targeting lymphoma  and leukemia-associated antigens. Others are the results of clinical  observations - e.g., the association between graft-versus-host-  disease (GVHD) and durable remissions that have led to creative  clinical experiments such as donor leukocyte infusions (DLI). Attempts  to unravel the biological events that underlie the responses seen in  patients with relapsed chronic myelogenous leukemia treated with DLI  are likely to provide the basis for future refinements in this  clinical approach. Hopefully, improved response rates and reduced  toxicity will result. The power of the immunologic response in  controlling malignant disease is underscored in the chapter on  post-transplant immunotherapy. The complex immunologic process that  results in clinical GVHD may be dissected and engineered to provide  clinical benefits that include, in addition to its antineoplastic  effects, the amelioration of its clinical manifestations. Better  control of GVHD with less global immunosuppression will facilitate the  use of mismatched and unrelated donors. This area of investigation  perfectly illustrates the continued interplay between the laboratory  and the clinic. The continued cross-fertilization of ideas between  immunologists, molecular biologists and clinical investigators is  likely to yield important advances in this field for years to come.  \u003cbr\u003e  Possible applications of stem cell transplantation continue to grow  with the identification of alternative sources of stem cells and the  potential to engineer and\/orexpand the graft. Although the use of  unrelated and mismatched donors continues to increase, the  possibilities associated with umbilical cord blood transplantation are  legion, especially if stem cells can be expanded ex vivo to provide  grafts for full-sized adults. Using techniques in which contaminating  malignant cells may be eliminated from autografts through positive  selection, autologous transplantation may prove highly effective,  especially when coupled with post-transplant immunotherapy. Some of  these same methodologies have helped facilitate the use of autologous  grafts for transplantation in patients with chronic myelogenous  leukemia without allogeneic donors. \u003cbr\u003e  Advances in the supportive care of transplant patients, including the  pretransplant identification of those at risk from pulmonary  complications and the use of cytokines to speed engraftment, have  reduced morbidity and mortality to such a degree that it is  appropriate to consider high-dose therapy and stem cell reconstitution  in patients with nonmalignant diseases. The impressive advances that  have occurred in transplantation for thalassemia are described by  pioneers in their area of investigation. The burgeoning field of  transplantation for autoimmune disorders, including its immunobiologic  basis and soon-to- be-realized clinical potential, is also summarized.  Continued progress in the use of high-dose therapy with stem cell  rescue for the treatment of pediatric tumors, which derives in part  from improved supportive care, is detailed. \u003cbr\u003e  The sobering voice of the health care economists underscores the  necessary limitations to our seemingly unbridled imagination. Cost-  consciousness and financial know-how will need to be reflected in  future study designs. Given the seemingly endless applications of our  technology, strategies to insure its cost-effectiveness will be  necessary. Continued financial support for laboratory investigation  and for the clinical experiments they generate will be required if we  are to go forward. \u003cem\u003eBlood Stem Cell Transplantation\u003c\/em\u003e lays the  foundation for many of these future advances; it is incumbent upon us  all to insure its realization.\u003c\/p\u003e \u003ch3\u003eDetails\u003c\/h3\u003e \u003cp\u003ePublished by: Springer\u003c\/p\u003e \u003cp\u003ePublication Date: 2012-10-08\u003c\/p\u003e \u003cp\u003eFormat: Paperback\u003c\/p\u003e \u003cp\u003e ISBN-10: 9781461379164\u003c\/p\u003e \u003cp\u003eISBN-13: 9781461379164\u003c\/p\u003e \u003cp\u003eDOI: 10.1007\/978-1-4615-6349-5\u003c\/p\u003e \u003cp\u003eDimensions: 235cm x155cm\u003c\/p\u003e \u003cp\u003ePages: 416\u003c\/p\u003e ","brand":"Springer","offers":[{"title":"Default Title","offer_id":44358921191564,"sku":"9781461379164","price":297.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0710\/9545\/1788\/files\/9781461379164_2cafc212-2fe5-44c6-b066-affd77a170f7.jpg?v=1755097297","url":"https:\/\/lateknightbooks.com\/products\/9781461379164","provider":"Late Knight Books and Services, LLC","version":"1.0","type":"link"}